Sheep, wolf, or werewolf: Cancer stem cells and the epithelial-to-mesenchymal transition

Cancer Letters

Volumn 341, Issue 1, 2013, Pages 16-23

  Chang, Jeffrey T ^a,b   Mani, Sendurai A ^c  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cancer stem cells; Cellular plasticity; EMT; Epithelial mesenchymal transition

Indexed keywords

CYTOTOXIC AGENT; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METFORMIN; PROTEIN INHIBITOR; RAS PROTEIN INHIBITOR; RETINOIC ACID; SALINOMYCIN; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER CELL; CANCER RESISTANCE; CANCER STEM CELL; CANCER THERAPY; CELL DIFFERENTIATION; CELL RENEWAL; CELL SUBPOPULATION; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; FIBROBLAST; HUMAN; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MULTIPOTENT STEM CELL; NONHUMAN; PANCREAS CANCER; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; SHORT SURVEY; TUMOR SEEDING;

OVIS ARIES;

EID: 84887167622     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.03.004     Document Type: Review

References (159)

1. Sell S. Stem cell origin of cancer and differentiation therapy. Crit. Rev. Oncol. Hematol. 2004, 51:1-28.
2. Lapidot T., Sirard C., Vormoor J., Murdoch B., Hoang T., Caceres-Cortes J., Minden M., Paterson B., Caligiuri M.A., Dick J.E. A cell initiating human acute myeloid leukemia after transplantation into SCID mice. Nature 1994, 367:645-648.
3. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 1997, 3:730-737.
4. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111.
5. Clarke M.F., Dick J.E., Dirks P.B., Eaves C.J., Jamieson C.H., Jones D.L., Visvader J., Weissman I.L., Wahl G.M. Cancer stem cells - perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res. 2006, 66:9339-9344.
6. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 2003, 100:3983-3988.
7. Singh S.K., Hawkins C., Clarke I.D., Squire J.A., Bayani J., Hide T., Henkelman R.M., Cusimano M.D., Dirks P.B. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.
8. Singh S.K., Clarke I.D., Terasaki M., Bonn V.E., Hawkins C., Squire J., Dirks P.B. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003, 63:5821-5828.
9. Fang D., Nguyen T.K., Leishear K., Finko R., Kulp A.N., Hotz S., van Belle P.A., Xu X., Elder D.E., Herlyn M. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res. 2005, 65:9328-9337.
10. Collins A.T., Berry P.A., Hyde C., Stower M.J., Maitland N.J. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005, 65:10946-10951.
11. + prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 2006, 25:1696-1708.
12. O'Brien C.A., Pollett A., Gallinger S., Dick J.E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007, 445:106-110.
13. Ricci-Vitiani L., Lombardi D.G., Pilozzi E., Biffoni M., Todaro M., Peschle C., De Maria R. Identification and expansion of human colon-cancer-initiating cells. Nature 2007, 445:111-115.
14. Li C., Heidt D.G., Dalerba P., Burant C.F., Zhang L., Adsay V., Wicha M., Clarke M.F., Simeone D.M. Identification of pancreatic cancer stem cells. Cancer Res. 2007, 67:1030-1037.
15. Hermann P.C., Huber S.L., Herrler T., Aicher A., Ellwart J.W., Guba M., Bruns C.J., Heeschen C. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007, 1:313-323.
16. Eramo A., Lotti F., Sette G., Pilozzi E., Biffoni M., Di Virgilio A., Conticello C., Ruco L., Peschle C., De Maria R. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 2008, 15:504-514.
17. Aruffo A., Stamenkovic I., Melnick M., Underhill C.B., Seed B. CD44 is the principal cell surface receptor for hyaluronate. Cell 1990, 61:1303-1313.
18. Hughes E.N., August J.T. Characterization of plasma membrane proteins identified by monoclonal antibodies. J. Biol. Chem. 1981, 256:664-671.
19. Zhang S., Balch C., Chan M.W., Lai H.C., Matei D., Schilder J.M., Yan P.S., Huang T.H., Nephew K.P. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 2008, 68:4311-4320.
20. Chen K.L., Pan F., Jiang H., Chen J.F., Pei L., Xie F.W., Liang H.J. Highly enriched CD133(+)CD44(+) stem-like cells with CD133(+)CD44(high) metastatic subset in HCT116 colon cancer cells. Clin. Exp. Metastasis 2011, 28:751-763.
21. Jaggupilli A., Elkord E. Significance of CD44 and CD24 as cancer stem cell markers: an enduring ambiguity. Clin. Dev. Immunol. 2012, 2012:708036.
22. - progenitor cells. Blood 1991, 77:1218-1227.
23. Boiko A.D., Razorenova O.V., van de Rijn M., Swetter S.M., Johnson D.L., Ly D.P., Butler P.D., Yang G.P., Joshua B., Kaplan M.J., Longaker M.T., Weissman I.L. Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature 2010, 466:133-137.
24. May C.D., Sphyris N., Evans K.W., Werden S.J., Guo W., Mani S.A. Epithelial-mesenchymal transition and cancer stem cells: a dangerously dynamic duo in breast cancer progression. Breast Cancer Research: BCR 2011, 13:202.
25. Thiery J.P., Sleeman J.P. Complex networks orchestrate epithelial-mesenchymal transitions. Nature Reviews. Molecular Cell Biology 2006, 7:131-142.
26. Boyer B., Thiery J.P. Epithelium-mesenchyme interconversion as example of epithelial plasticity. APMIS 1993, 101:257-268.
27. Davies J.A. Mesenchyme to epithelium transition during development of the mammalian kidney tubule. Acta Anat. (Basel) 1996, 156:187-201.
28. Yang J., Weinberg R.A. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev. Cell 2008, 14:818-829.
29. Huber M.A., Kraut N., Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr. Opin. Cell Biol. 2005, 17:548-558.
30. Thiery J.P. Epithelial-mesenchymal transitions in development and pathologies. Curr. Opin. Cell Biol. 2003, 15:740-746.
31. Stoker M., Perryman M. An epithelial scatter factor released by embryo fibroblasts. J. Cell Sci. 1985, 77:209-223.
32. Thompson E.W., Paik S., Brunner N., Sommers C.L., Zugmaier G., Clarke R., Shima T.B., Torri J., Donahue S., Lippman M.E., et al. Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J. Cell Physiol. 1992, 150:534-544.
33. Tarin D., Thompson E.W., Newgreen D.F. The fallacy of epithelial mesenchymal transition in neoplasia. Cancer Res. 2005, 65:5996-6000. Discussion 6000-5991.
34. Christiansen J.J., Rajasekaran A.K. Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res. 2006, 66:8319-8326.
35. Ledford H. Cancer theory faces doubts. Nature 2011, 472:273.
36. Xue C., Plieth D., Venkov C., Xu C., Neilson E.G. The gatekeeper effect of epithelial-mesenchymal transition regulates the frequency of breast cancer metastasis. Cancer Res. 2003, 63:3386-3394.
37. Pantel K., Brakenhoff R.H. Dissecting the metastatic cascade. Nature Rev. Cancer 2004, 4:448-456.
38. Hay E.D., Zuk A. Transformations between epithelium and mesenchyme: normal, pathological, and experimentally induced. Am. J. Kidney Dis. 1995, 26:678-690.
39. Robson E.J., Khaled W.T., Abell K., Watson C.J. Epithelial-to-mesenchymal transition confers resistance to apoptosis in three murine mammary epithelial cell lines. Differentiation 2006, 74:254-264.
40. Thompson E.W., Newgreen D.F., Tarin D. Carcinoma invasion and metastasis: a role for epithelial-mesenchymal transition?. Cancer Res. 2005, 65:5991-5995. Discussion 5995.
41. Kang Y., Massague J. Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 2004, 118:277-279.
42. Perl A.K., Wilgenbus P., Dahl U., Semb H., Christofori G. A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature 1998, 392:190-193.
43. Thiery J.P. Epithelial-mesenchymal transitions in tumour progression. Nature Rev. Cancer 2002, 2:442-454.
44. Droufakou S., Deshmane V., Roylance R., Hanby A., Tomlinson I., Hart I.R. Multiple ways of silencing E-cadherin gene expression in lobular carcinoma of the breast. Int. J. Cancer 2001, 92:404-408.
45. Berx G., Cleton-Jansen A.M., Strumane K., de Leeuw W.J., Nollet F., van Roy F., Cornelisse C. E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. Oncogene 1996, 13:1919-1925.
46. Huiping C., Sigurgeirsdottir J.R., Jonasson J.G., Eiriksdottir G., Johannsdottir J.T., Egilsson V., Ingvarsson S. Chromosome alterations and E-cadherin gene mutations in human lobular breast cancer. Br. J. Cancer 1999, 81:1103-1110.
47. Graff J.R., Gabrielson E., Fujii H., Baylin S.B., Herman J.G. Methylation patterns of the E-cadherin 5' CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression. J. Biol. Chem. 2000, 275:2727-2732.
48. Guilford P., Hopkins J., Harraway J., McLeod M., McLeod N., Harawira P., Taite H., Scoular R., Miller A., Reeve A.E. E-cadherin germline mutations in familial gastric cancer. Nature 1998, 392:402-405.
49. Sleeman J.P., Thiery J.P. SnapShot: the epithelial-mesenchymal transition. Cell 2011, 145:162 e161.
50. Oft M., Peli J., Rudaz C., Schwarz H., Beug H., Reichmann E. TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev. 1996, 10:2462-2477.
51. Zavadil J., Bottinger E.P. TGF-beta and epithelial-to-mesenchymal transitions. Oncogene 2005, 24:5764-5774.
52. Reya T., Clevers H. Wnt signalling in stem cells and cancer. Nature 2005, 434:843-850.
53. Thiery J.P., Acloque H., Huang R.Y., Nieto M.A. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-890.
54. Gorsch S.M., Memoli V.A., Stukel T.A., Gold L.I., Arrick B.A. Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer. Cancer Res. 1992, 52:6949-6952.
55. Oft M., Heider K.H., Beug H. TGFbeta signaling is necessary for carcinoma cell invasiveness and metastasis. Curr. Biol. 1998, 8:1243-1252.
56. Massague J., Blain S.W., Lo R.S. TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 2000, 103:295-309.
57. Derynck R., Akhurst R.J., Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat. Genet. 2001, 29:117-129.
58. Cano A., Perez-Moreno M.A., Rodrigo I., Locascio A., Blanco M.J., del Barrio M.G., Portillo F., Nieto M.A. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat. Cell Biol. 2000, 2:76-83.
59. Vincent T., Neve E.P., Johnson J.R., Kukalev A., Rojo F., Albanell J., Pietras K., Virtanen I., Philipson L., Leopold P.L., Crystal R.G., de Herreros A.G., Moustakas A., Pettersson R.F., Fuxe J. A SNAIL1-SMAD3/4 transcriptional repressor complex promotes TGF-beta mediated epithelial-mesenchymal transition. Nat. Cell Biol. 2009, 11:943-950.
60. Batlle E., Sancho E., Franci C., Dominguez D., Monfar M., Baulida J., Garcia De Herreros A. The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat. Cell Biol. 2000, 2:84-89.
61. Giroldi L.A., Bringuier P.P., de Weijert M., Jansen C., van Bokhoven A., Schalken J.A. Role of E boxes in the repression of E-cadherin expression. Biochem. Biophys. Res. Commun. 1997, 241:453-458.
62. Moreno-Bueno G., Peinado H., Molina P., Olmeda D., Cubillo E., Santos V., Palacios J., Portillo F., Cano A. The morphological and molecular features of the epithelial-to-mesenchymal transition. Nat. Protoc. 2009, 4:1591-1613.
63. Ouyang G., Wang Z., Fang X., Liu J., Yang C.J. Molecular signaling of the epithelial to mesenchymal transition in generating and maintaining cancer stem cells. Cell Mol. Life Sci. 2010, 67:2605-2618.
64. Hajra K.M., Chen D.Y., Fearon E.R. The SLUG zinc-finger protein represses E-cadherin in breast cancer. Cancer Res. 2002, 62:1613-1618.
65. Bolos V., Peinado H., Perez-Moreno M.A., Fraga M.F., Esteller M., Cano A. The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors. J. Cell Sci. 2003, 116:499-511.
66. Eger A., Aigner K., Sonderegger S., Dampier B., Oehler S., Schreiber M., Berx G., Cano A., Beug H., Foisner R. DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells. Oncogene 2005, 24:2375-2385.
67. Comijn J., Berx G., Vermassen P., Verschueren K., van Grunsven L., Bruyneel E., Mareel M., Huylebroeck D., van Roy F. The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol. Cell 2001, 7:1267-1278.
68. Rosivatz E., Becker I., Specht K., Fricke E., Luber B., Busch R., Hofler H., Becker K.F. Differential expression of the epithelial-mesenchymal transition regulators snail, SIP1, and twist in gastric cancer. Am. J. Pathol. 2002, 161:1881-1891.
69. Yang J., Mani S.A., Donaher J.L., Ramaswamy S., Itzykson R.A., Come C., Savagner P., Gitelman I., Richardson A., Weinberg R.A. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004, 117:927-939.
70. Polyak K., Weinberg R.A. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nature Rev. Cancer 2009, 9:265-273.
71. Lebret S.C., Newgreen D.F., Thompson E.W., Ackland M.L. Induction of epithelial to mesenchymal transition in PMC42-LA human breast carcinoma cells by carcinoma-associated fibroblast secreted factors. Breast Cancer Res. 2007, 9:R19.
72. Giannoni E., Bianchini F., Calorini L., Chiarugi P. Cancer associated fibroblasts exploit reactive oxygen species through a proinflammatory signature leading to epithelial mesenchymal transition and stemness. Antioxid. Redox Signal 2011, 14:2361-2371.
73. Dudas J., Bitsche M., Schartinger V., Falkeis C., Sprinzl G.M., Riechelmann H. Fibroblasts produce brain-derived neurotrophic factor and induce mesenchymal transition of oral tumor cells. Oral Oncol. 2011, 47:98-103.
74. Giannoni E., Bianchini F., Masieri L., Serni S., Torre E., Calorini L., Chiarugi P. Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness. Cancer Res. 2010, 70:6945-6956.
75. Taube J.H., Herschkowitz J.I., Komurov K., Zhou A.Y., Gupta S., Yang J., Hartwell K., Onder T.T., Gupta P.B., Evans K.W., Hollier B.G., Ram P.T., Lander E.S., Rosen J.M., Weinberg R.A., Mani S.A. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc. Natl. Acad. Sci. USA 2010, 107:15449-15454.
76. Moreno-Bueno G., Cubillo E., Sarrio D., Peinado H., Rodriguez-Pinilla S.M., Villa S., Bolos V., Jorda M., Fabra A., Portillo F., Palacios J., Cano A. Genetic profiling of epithelial cells expressing E-cadherin repressors reveals a distinct role for Snail, Slug, and E47 factors in epithelial-mesenchymal transition. Cancer Res. 2006, 66:9543-9556.
77. Mani S.A., Guo W., Liao M.J., Eaton E.N., Ayyanan A., Zhou A.Y., Brooks M., Reinhard F., Zhang C.C., Shipitsin M., Campbell L.L., Polyak K., Brisken C., Yang J., Weinberg R.A. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715.
78. Morel A.P., Lievre M., Thomas C., Hinkal G., Ansieau S., Puisieux A. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One 2008, 3:e2888.
79. Wellner U., Schubert J., Burk U.C., Schmalhofer O., Zhu F., Sonntag A., Waldvogel B., Vannier C., Darling D., zur Hausen A., Brunton V.G., Morton J., Sansom O., Schuler J., Stemmler M.P., Herzberger C., Hopt U., Keck T., Brabletz S., Brabletz T. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat. Cell Biol. 2009, 11:1487-1495.
80. Korinek V., Barker N., Moerer P., van Donselaar E., Huls G., Peters P.J., Clevers H. Depletion of epithelial stem-cell compartments in the small intestine of mice lacking Tcf-4. Nat. Genet. 1998, 19:379-383.
81. Fodde R., Brabletz T. Wnt/beta-catenin signaling in cancer stemness and malignant behavior. Curr. Opin. Cell Biol. 2007, 19:150-158.
82. Li J., Zhou B.P. Activation of beta-catenin and Akt pathways by Twist are critical for the maintenance of EMT associated cancer stem cell-like characters. BMC Cancer 2011, 11:49.
83. Cadigan K.M., Nusse R. Wnt signaling: a common theme in animal development. Genes Dev. 1997, 11:3286-3305.
84. Liebner S., Cattelino A., Gallini R., Rudini N., Iurlaro M., Piccolo S., Dejana E. Beta-catenin is required for endothelial-mesenchymal transformation during heart cushion development in the mouse. J. Cell Biol. 2004, 166:359-367.
85. Haegel H., Larue L., Ohsugi M., Fedorov L., Herrenknecht K., Kemler R. Lack of beta-catenin affects mouse development at gastrulation. Development 1995, 121:3529-3537.
86. Roose J., Clevers H. TCF transcription factors: molecular switches in carcinogenesis. Biochim. Biophys. Acta 1999, 1424:M23-37.
87. Bienz M., Clevers H. Linking colorectal cancer to Wnt signaling. Cell 2000, 103:311-320.
88. Brabletz T., Hlubek F., Spaderna S., Schmalhofer O., Hiendlmeyer E., Jung A., Kirchner T. Invasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem cells and beta-catenin. Cells Tissues Organs 2005, 179:56-65.
89. Scheel C., Weinberg R.A. Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. Semin Cancer Biol. 2012.
90. Zhou B.P., Deng J., Xia W., Xu J., Li Y.M., Gunduz M., Hung M.C. Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nature Cell Biol. 2004, 6:931-940.
91. Yook J.I., Li X.Y., Ota I., Hu C., Kim H.S., Kim N.H., Cha S.Y., Ryu J.K., Choi Y.J., Kim J., Fearon E.R., Weiss S.J. A Wnt-Axin2-GSK3beta cascade regulates Snail1 activity in breast cancer cells. Nat. Cell Biol. 2006, 8:1398-1406.
92. Conacci-Sorrell M., Simcha I., Ben-Yedidia T., Blechman J., Savagner P., Ben-Ze'ev A. Autoregulation of E-cadherin expression by cadherin-cadherin interactions: the roles of beta-catenin signaling, Slug, and MAPK. J. Cell Biol. 2003, 163:847-857.
93. Onder T.T., Gupta P.B., Mani S.A., Yang J., Lander E.S., Weinberg R.A. Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res. 2008, 68:3645-3654.
94. Eger A., Stockinger A., Schaffhauser B., Beug H., Foisner R. Epithelial mesenchymal transition by c-Fos estrogen receptor activation involves nuclear translocation of beta-catenin and upregulation of beta-catenin/lymphoid enhancer binding factor-1 transcriptional activity. J. Cell Biol. 2000, 148:173-188.
95. Gumbiner B.M. Regulation of cadherin adhesive activity. J. Cell Biol. 2000, 148:399-404.
96. Novak A., Hsu S.C., Leung-Hagesteijn C., Radeva G., Papkoff J., Montesano R., Roskelley C., Grosschedl R., Dedhar S. Cell adhesion and the integrin-linked kinase regulate the LEF-1 and beta-catenin signaling pathways. Proc. Natl. Acad. Sci. USA 1998, 95:4374-4379.
97. Miyoshi A., Kitajima Y., Kido S., Shimonishi T., Matsuyama S., Kitahara K., Miyazaki K. Snail accelerates cancer invasion by upregulating MMP expression and is associated with poor prognosis of hepatocellular carcinoma. Br. J. Cancer 2005, 92:252-258.
98. Elloul S., Elstrand M.B., Nesland J.M., Trope C.G., Kvalheim G., Goldberg I., Reich R., Davidson B. Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma. Cancer 2005, 103:1631-1643.
99. Spaderna S., Schmalhofer O., Hlubek F., Berx G., Eger A., Merkel S., Jung A., Kirchner T., Brabletz T. A transient, EMT-linked loss of basement membranes indicates metastasis and poor survival in colorectal cancer. Gastroenterology 2006, 131:830-840.
100. Pece S., Tosoni D., Confalonieri S., Mazzarol G., Vecchi M., Ronzoni S., Bernard L., Viale G., Pelicci P.G., Di Fiore P.P. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 2010, 140:62-73.
101. Blanco M.J., Moreno-Bueno G., Sarrio D., Locascio A., Cano A., Palacios J., Nieto M.A. Correlation of Snail expression with histological grade and lymph node status in breast carcinomas. Oncogene 2002, 21:3241-3246.
102. Martin T.A., Goyal A., Watkins G., Jiang W.G. Expression of the transcription factors snail, slug, and twist and their clinical significance in human breast cancer. Ann. Surg. Oncol. 2005, 12:488-496.
103. Aktas B., Tewes M., Fehm T., Hauch S., Kimmig R., Kasimir-Bauer S. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res. 2009, 11:R46.
104. Kasimir-Bauer S., Hoffmann O., Wallwiener D., Kimmig R., Fehm T. Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells. Breast Cancer Res. 2012, 14:R15.
105. Balic M., Lin H., Young L., Hawes D., Giuliano A., McNamara G., Datar R.H., Cote R.J. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin. Cancer Res. 2006, 12:5615-5621.
106. Moody S.E., Perez D., Pan T.C., Sarkisian C.J., Portocarrero C.P., Sterner C.J., Notorfrancesco K.L., Cardiff R.D., Chodosh L.A. The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell 2005, 8:197-209.
107. Yang M.H., Chang S.Y., Chiou S.H., Liu C.J., Chi C.W., Chen P.M., Teng S.C., Wu K.J. Overexpression of NBS1 induces epithelial-mesenchymal transition and co-expression of NBS1 and Snail predicts metastasis of head and neck cancer. Oncogene 2007, 26:1459-1467.
108. Mandal M., Myers J.N., Lippman S.M., Johnson F.M., Williams M.D., Rayala S., Ohshiro K., Rosenthal D.I., Weber R.S., Gallick G.E., El-Naggar A.K. Epithelial to mesenchymal transition in head and neck squamous carcinoma: association of Src activation with E-cadherin down-regulation, vimentin expression, and aggressive tumor features. Cancer 2008, 112:2088-2100.
109. Croker A.K., Allan A.L. Cancer stem cells: implications for the progression and treatment of metastatic disease. J. Cell Mol. Med. 2008, 12:374-390.
110. Li X., Lewis M.T., Huang J., Gutierrez C., Osborne C.K., Wu M.F., Hilsenbeck S.G., Pavlick A., Zhang X., Chamness G.C., Wong H., Rosen J., Chang J.C. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J. Natl. Cancer Inst. 2008, 100:672-679.
111. Creighton C.J., Li X., Landis M., Dixon J.M., Neumeister V.M., Sjolund A., Rimm D.L., Wong H., Rodriguez A., Herschkowitz J.I., Fan C., Zhang X., He X., Pavlick A., Gutierrez M.C., Renshaw L., Larionov A.A., Faratian D., Hilsenbeck S.G., Perou C.M., Lewis M.T., Rosen J.M., Chang J.C. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc. Natl. Acad. Sci. USA 2009, 106:13820-13825.
112. Wang Z., Li Y., Kong D., Banerjee S., Ahmad A., Azmi A.S., Ali S., Abbruzzese J.L., Gallick G.E., Sarkar F.H. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res. 2009, 69:2400-2407.
113. Rho J.K., Choi Y.J., Lee J.K., Ryoo B.Y., Na B.Y., Yang S.H., Kim C.H., Lee J.C. Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line. Lung Cancer 2009, 63:219-226.
114. Aulmann S., Waldburger N., Penzel R., Andrulis M., Schirmacher P., Sinn H.P. Reduction of CD44(+)/CD24(-) breast cancer cells by conventional cytotoxic chemotherapy. Hum. Pathol. 2010, 41:574-581.
115. Gil J., Stembalska A., Pesz K.A., Sasiadek M.M. Cancer stem cells: the theory and perspectives in cancer therapy. J. Appl. Genet. 2008, 49:193-199.
116. Pardal R., Clarke M.F., Morrison S.J. Applying the principles of stem-cell biology to cancer. Nature Rev. Cancer 2003, 3:895-902.
117. Croker A.K., Goodale D., Chu J., Postenka C., Hedley B.D., Hess D.A., Allan A.L. High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. J. Cell. Mol. Med. 2009, 13:2236-2252.
118. Hu L., McArthur C., Jaffe R.B. Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant. Brit. J. Cancer 2010, 102:1276-1283.
119. Dean M., Fojo T., Bates S. Tumour stem cells and drug resistance. Nature Rev. Cancer 2005, 5:275-284.
120. Yang A.D., Fan F., Camp E.R., van Buren G., Liu W., Somcio R., Gray M.J., Cheng H., Hoff P.M., Ellis L.M. Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin. Cancer Res. 2006, 12:4147-4153.
121. Kajiyama H., Shibata K., Terauchi M., Yamashita M., Ino K., Nawa A., Kikkawa F. Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int. J. Oncol. 2007, 31:277-283.
122. Cheng G.Z., Chan J., Wang Q., Zhang W., Sun C.D., Wang L.H. Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. Cancer Res. 2007, 67:1979-1987.
123. Kajita M., McClinic K.N., Wade P.A. Aberrant expression of the transcription factors snail and slug alters the response to genotoxic stress. Mol. Cell Biol. 2004, 24:7559-7566.
124. Kurrey N.K., Jalgaonkar S.P., Joglekar A.V., Ghanate A.D., Chaskar P.D., Doiphode R.Y., Bapat S.A. Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells 2009, 27:2059-2068.
125. Arumugam T., Ramachandran V., Fournier K.F., Wang H., Marquis L., Abbruzzese J.L., Gallick G.E., Logsdon C.D., McConkey D.J., Choi W. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res. 2009, 69:5820-5828.
126. Haddad Y., Choi W., McConkey D.J. Delta-crystalline enhancer binding factor 1 controls the epithelial to mesenchymal transition phenotype and resistance to the epidermal growth factor receptor inhibitor erlotinib in human head and neck squamous cell carcinoma lines. Clin. Cancer Res. 2009, 15:532-542.
127. Shah A.N., Summy J.M., Zhang J., Park S.I., Parikh N.U., Gallick G.E. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann. Surg. Oncol. 2007, 14:3629-3637.
128. Maestro R., Dei Tos A.P., Hamamori Y., Krasnokutsky S., Sartorelli V., Kedes L., Doglioni C., Beach D.H., Hannon G.J. Twist is a potential oncogene that inhibits apoptosis. Genes Dev. 1999, 13:2207-2217.
129. Wu W.S., Heinrichs S., Xu D., Garrison S.P., Zambetti G.P., Adams J.M., Look A.T. Slug antagonizes p53-mediated apoptosis of hematopoietic progenitors by repressing puma. Cell 2005, 123:641-653.
130. Bandyopadhyay A., Wang L., Agyin J., Tang Y., Lin S., Yeh I.T., De K., Sun L.Z. Doxorubicin in combination with a small TGFbeta inhibitor: a potential novel therapy for metastatic breast cancer in mouse models. PLoS One 2010, 5:e10365.
131. Barr S., Thomson S., Buck E., Russo S., Petti F., Sujka-Kwok I., Eyzaguirre A., Rosenfeld-Franklin M., Gibson N.W., Miglarese M., Epstein D., Iwata K.K., Haley J.D. Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions. Clin. Exp. Metastasis 2008, 25:685-693.
132. Frederick B.A., Helfrich B.A., Coldren C.D., Zheng D., Chan D., Bunn P.A., Raben D. Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma. Mol. Cancer Ther. 2007, 6:1683-1691.
133. Shrader M., Pino M.S., Brown G., Black P., Adam L., Bar-Eli M., Dinney C.P., McConkey D.J. Molecular correlates of gefitinib responsiveness in human bladder cancer cells. Mol. Cancer Therap. 2007, 6:277-285.
134. Singh A., Greninger P., Rhodes D., Koopman L., Violette S., Bardeesy N., Settleman J. A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell 2009, 15:489-500.
135. + breast cancer-initiating cells to radiation. J. Nat. Cancer Inst. 2006, 98:1777-1785.
136. Woodward W.A., Chen M.S., Behbod F., Alfaro M.P., Buchholz T.A., Rosen J.M. WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc. Natl. Acad. Sci. USA 2007, 104:618-623.
137. Witta S.E., Gemmill R.M., Hirsch F.R., Coldren C.D., Hedman K., Ravdel L., Helfrich B., Dziadziuszko R., Chan D.C., Sugita M., Chan Z., Baron A., Franklin W., Drabkin H.A., Girard L., Gazdar A.F., Minna J.D., Bunn P.A. Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res. 2006, 66:944-950.
138. Li Q.Q., Xu J.D., Wang W.J., Cao X.X., Chen Q., Tang F., Chen Z.Q., Liu X.P., Xu Z.D. Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells. Clin. Cancer Res. 2009, 15:2657-2665.
139. Adam L., Zhong M., Choi W., Qi W., Nicoloso M., Arora A., Calin G., Wang H., Siefker-Radtke A., McConkey D., Bar-Eli M., Dinney C. MiR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin. Cancer Res. 2009, 15:5060-5072.
140. Cochrane D.R., Spoelstra N.S., Howe E.N., Nordeen S.K., Richer J.K. MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol. Cancer Ther. 2009, 8:1055-1066.
141. Schickel R., Park S.M., Murmann A.E., Peter M.E. MiR-200c regulates induction of apoptosis through CD95 by targeting FAP-1. Mol. Cell 2010, 38:908-915.
142. Tryndyak V.P., Beland F.A., Pogribny I.P. E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells. Int. J. Cancer 2010, 126:2575-2583.
143. Davalos V., Moutinho C., Villanueva A., Boque R., Silva P., Carneiro F., Esteller M. Dynamic epigenetic regulation of the microRNA-200 family mediates epithelial and mesenchymal transitions in human tumorigenesis. Oncogene 2012, 31:2062-2074.
144. Behbod F., Rosen J.M. Will cancer stem cells provide new therapeutic targets?. Carcinogenesis 2005, 26:703-711.
145. Brabletz T. To differentiate or not - routes towards metastasis. Nature reviews. Cancer 2012.
146. Hirsch H.A., Iliopoulos D., Tsichlis P.N., Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 2009, 69:7507-7511.
147. Iliopoulos D., Hirsch H.A., Struhl K. Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res. 2011, 71:3196-3201.
148. Gupta P.B., Onder T.T., Jiang G., Tao K., Kuperwasser C., Weinberg R.A., Lander E.S. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009, 138:645-659.
149. Chua K.N., Ma J., Thiery J.P. Targeted therapies in control of EMT in carcinoma and fibrosis. Drug Discovery Today: Dis. Mech. 2008, 4:261-267.
150. DiMeo T.A., Anderson K., Phadke P., Fan C., Perou C.M., Naber S., Kuperwasser C. A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer. Cancer Res. 2009, 69:5364-5373.
151. Shida T., Furuya M., Nikaido T., Hasegawa M., Koda K., Oda K., Miyazaki M., Kishimoto T., Nakatani Y., Ishikura H. Sonic Hedgehog-Gli1 signaling pathway might become an effective therapeutic target in gastrointestinal neuroendocrine carcinomas. Cancer Biol. Ther. 2006, 5:1530-1538.
152. Feldmann G., Fendrich V., McGovern K., Bedja D., Bisht S., Alvarez H., Koorstra J.B., Habbe N., Karikari C., Mullendore M., Gabrielson K.L., Sharma R., Matsui W., Maitra A. An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer. Mol. Cancer Ther. 2008, 7:2725-2735.
153. Finn R.S., Dering J., Ginther C., Wilson C.A., Glaspy P., Tchekmedyian N., Slamon D.J. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro. Breast Cancer Res. Treat. 2007, 105:319-326.
154. Mueller M.T., Hermann P.C., Witthauer J., Rubio-Viqueira B., Leicht S.F., Huber S., Ellwart J.W., Mustafa M., Bartenstein P., D'Haese J.G., Schoenberg M.H., Berger F., Jauch K.W., Hidalgo M., Heeschen C. Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer. Gastroenterology 2009, 137:1102-1113.
155. Huang M.E., Ye Y.C., Chen S.R., Chai J.R., Lu J.X., Zhoa L., Gu L.J., Wang Z.Y. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988, 72:567-572.
156. Bennett D.C., Dexter T.J., Ormerod E.J., Hart I.R. Increased experimental metastatic capacity of a murine melanoma following induction of differentiation. Cancer Res. 1986, 46:3239-3244.
157. Chaffer C.L., Brennan J.P., Slavin J.L., Blick T., Thompson E.W., Williams E.D. Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2. Cancer Res. 2006, 66:11271-11278.
158. Tomaskovic-Crook E., Thompson E.W., Thiery J.P. Epithelial to mesenchymal transition and breast cancer. Breast Cancer Res: BCR 2009, 11:213.
159. Shackleton M. Moving targets that drive cancer progression. N. Engl. J. Med. 2010, 363:885-886.